* CHMP grants positive opinion for shorter treatment duration with Abbvie’s VIEKIRAX
(ombitasvir/paritaprevir/ritonavir tablets) for patients with genotype 4 chronic hepatitis C
with compensated…
The post BRIEF-Abbvie says CHMP grants positive opinion for shorter treatment duration with VIEKIRAX appeared first on NASDAQ.